Clinical Trial Update: Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis [Phase 1, Phase 2]

View source ↗

Summary

Safety and tolerability study of COVA322 in stable chronic moderate-to-severe plaque psoriasis was terminated after Phase 1/2, according to the trial record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• COVA322

Snippet

Sponsor: Covagen | Conditions: Plaque Psoriasis | Phase 1, Phase 2 | Status: TERMINATED